We are live on ! Find out more
EGRX

Eagle Pharmaceuticals, Inc.
EGRX

Delisted

EGRX was delisted on the 2nd of October, 2024.

Back to rankings

149 hedge funds and large institutions have $1.31B invested in Eagle Pharmaceuticals, Inc. in 2016 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 48 increasing their positions, 46 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

94% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 16

12% more call options, than puts

Call options by funds: $20.7M | Put options by funds: $18.4M

12% more capital invested

Capital invested by funds: $1.17B → $1.31B (+$136M)

9% more funds holding

Funds holding: 137 → 149 (+12)

4% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 46

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

Holders
149
Holders Change
+12
Holders Change %
+8.76%
% of All Funds
3.72%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.15%
New
31
Increased
48
Reduced
46
Closed
16
Calls
$20.7M
Puts
$18.4M
Net Calls
+$2.23M
Net Calls Change
-$8.96M

Top Buyers

Rank Fund Capital Flow
1
Victory Capital Management
Victory Capital Management
Texas
+$12.6M
2
CM
Castleark Management
Illinois
+$8.46M
3
State Street
State Street
Massachusetts
+$6.87M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$6.68M
5
BFA
BlackRock Fund Advisors
California
+$6.06M

Top Sellers

Rank Fund Capital Flow
1
PAI
ProQuest Associates IV
Florida
-$31.3M
2
O
OrbiMed
New York
-$26.5M
3
PC
PointState Capital
New York
-$21.3M
4
JCI
Jet Capital Investors
New York
-$9.44M
5
Morgan Stanley
Morgan Stanley
New York
-$8.74M
Name Holding Trade Value Shares
Change 		Change in
Stake
Asset Management One
151
Asset Management One
Japan
– -$6.28M -89,729 Closed
Capital Fund Management (CFM)
152
Capital Fund Management (CFM)
France
– -$5.77M -82,415 Closed
WSA
153
Wall Street Associates
California
– -$2.46M -35,200 Closed
American Century Companies
154
American Century Companies
Missouri
– -$1.92M -27,425 Closed
AA
155
ALPS Advisors
Colorado
– -$1.4M -19,933 Closed
VKH
156
Virtu KCG Holdings
New York
– -$642K -9,175 Closed
Squarepoint
157
Squarepoint
New York
– -$628K -8,971 Closed
SC
158
Sculptor Capital
New York
– -$406K -5,800 Closed
LSCM
159
LaSalle Street Capital Management
Illinois
– -$299K -4,278 Closed
UBS AM
160
UBS AM
Illinois
– -$245K -3,500 Closed
BFM
161
Boothbay Fund Management
New York
– -$220K -3,146 Closed
BCM
162
Bayesian Capital Management
New York
– -$212K -3,032 Closed
MWP
163
MYCIO Wealth Partners
Pennsylvania
– -$2K -22 Closed
Creative Planning
164
Creative Planning
Kansas
– -$1K -16 Closed
PFBT
165
Parkside Financial Bank & Trust
Missouri
– +$291 +4 New
3 4 5 6
7

EGRX Hedge Fund Activity: Q4 2016 in Review

149 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q4 2016, worth a combined $1.31B — up 12% from $1.17B a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new EGRX positions and 16 closed out — a net gain of 15 holders — while 48 added to existing stakes and 46 trimmed.

The largest buyer was Victory Capital Management, adding an estimated $12.6M. The largest seller was ProQuest Associates IV, cutting an estimated $31.3M.

  • 149 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q4 2016, up from 137 in Q3 2016.
  • Funds reported $1.31B of Eagle Pharmaceuticals, Inc. stock for Q4 2016, up 12% quarter-over-quarter.
  • 31 funds opened new Eagle Pharmaceuticals, Inc. positions in Q4 2016 and 16 closed out, a net change of +15 holders.
  • The largest Eagle Pharmaceuticals, Inc. buyer in Q4 2016 was Victory Capital Management, an estimated $12.6M added.
  • The largest Eagle Pharmaceuticals, Inc. seller in Q4 2016 was ProQuest Associates IV, an estimated $31.3M sold.

Based on aggregated 13F filings for Q4 2016.